09/856819 JC18 Rec'd PCT/PT0 24 MAY 2001

Attorney Docket No.: 5559.204-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Box PCT Commissioner for Patents Washington, DC 20231

Sir:

This is a request for filing a patent application under 35 U.S.C. 371 of the international application identified below:

INTERNATIONAL APPLICATION NO. PCT/DK99/00664		November 29, 1999		PRIORITY DATE CLAIMED November 27, 1998
APPLICANT(S)/INVENTOR(S)				
Given Name (First and middle (if any))	Family Name or Surname		Residence (City and Either State or Foreign Country)	
 Kirsten Allan Claus Crone Shamkant Anant Kim Jesper Andreas Sanne O. Schrøder Gitte 	 Bojsen Svendsen Fuglsang Patkar Borch Vind Petri Glad Budolfsen 		1. DK-2900 Hellerup, Denmark 2. DK-2970 Hørsholm, Denmark 3. DK-2990 Nivå, Denmark 4. DK-2800 Lyngby, Denmark 5. DK-3460 Birkerød, Denmark 6. DK-2880 Lyngby, Denmark 7. DK-2200 Copenhagen, Denmark 8. 2750 Ballerup, Denmark 9. DK-2000 Frederiksberg, Denmark	
TITLE OF THE INVENTION				
Lipolytic Enzyme·Variants				

- 1. This is a first submission of items concerning a filing under 35 U.S.C. 371
- 2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)).
- 3. The US has been elected by the expiration of 19 months from the priority date (Article 31).
- 4. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) has been communicated by the International Bureau on June 3, 2001.
- 5. An oath or declaration of the inventors is submitted herewith.
- 6. An Information Disclosure Statement is submitted herewith.
- 7. An Assignment and Recordation Form Cover Sheet are submitted herewith.

09/856819

8. A Preliminary Amendment is submitted herewith.

JC18 Rec'd PCT/PTO 2 4 MAY 2007

- 9. A computer-readable form of the sequence listing is submitted herewith.
- 10. The assignee of the present application is:

Novozymes A/S Krogshoejvej 36 DK-2880 Bagsvaerd Denmark

Applicants request that the assignee information be included in the published patent application.

11. Direct all correspondence to Customer Number 25908:



12. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO

\$ 860

CLAIMS FEE

 Total Claims: 29 - 20 = 9 x 18 =
 \$ 162

 Independent Claims: 3 - 3 = 0 x 80 =
 \$ 0

 Total Claims Fee:
 \$ 162

 FEE FOR RECORDING ASSIGNMENT
 \$ 40

TOTAL NATIONAL FEE

\$ 1062

13. Please charge the required fee, estimated to be \$1,062, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 24, 2001

Jeson I. Gerbell, Reg. No. 44,116 Novozymes North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123





Attorney Docket No. 5559.204-US

PATENT

IN THE UNITED STATED DESIGNATED/ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO.: PCT/DK99/00664

INTERNATIONAL FILING DATE: November 29, 1999

PRIORITY DATE: November 27, 1998

TITLE: Lipolytic Enzyme Variants

APPLICANT(S) FOR RO/US: Bojsen et al.

EXPRESS MAIL CERTIFICATE

Box PCT Commissioner for Patents Washington, DC 20231

Sir:

Express Mail Label No. EL 739103923 US

Date of Deposit: May 24, 2001

I hereby certify that the following attached papers or fee

- 1. Transmittal Letter to the DO/EO/US (in duplicate)
- 2. Executed Combined Declaration and Power of Attorney
- 3. Preliminary Amendment
- 4. Recordation Form Cover Sheet
- 5. Assignment
- 6. Paper Copy of Sequence Listing
- 7. Disk Containing Sequence Listing
- 8. Information Disclosure Statement
- 9. Form PTO 1449
- 10. Cited References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Kelley O'Patry

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novozymes North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017